Neuroplasticity

Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset

Retrieved on: 
Monday, April 1, 2024
Neuroplasticity, Stroke, Diagnosis, Depression, Plasma, CHDR, Rat, Patient, Research, Biomarker, DMT, AGN, Ifenprodil, Brain, Clinical trial, Safety, Algernon, USD, Pharmaceutical industry

Algernon established Algernon NeuroScience (AGN Neuro), a wholly owned subsidiary, to advance the research and development of the DMT stroke program in 2023.

Key Points: 
  • Algernon established Algernon NeuroScience (AGN Neuro), a wholly owned subsidiary, to advance the research and development of the DMT stroke program in 2023.
  • AGN Neuro has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2a DMT Stroke study.
  • The Phase 2a human stroke trial will study an intravenous sub-psychedelic dose of DMT in patients who are hospitalized after having suffered an acute ischemic stroke.
  • “Algernon is a global leader in this important area of research, and we look forward to further advancing the stroke program through our planned Phase 2a DMT Stroke study.”
    Subjects with a confirmed diagnosis of ischemic stroke will be randomized in blinded fashion to receive either DMT or placebo.

PurMinds Chief Innovation Officer to Speak at the Analytical Cannabis Educational Webinar about Next Generation Psychedelics and the Neurobiology of Neuroplastogens

Retrieved on: 
Wednesday, November 29, 2023
Trauma, Neuroplasticity, Depression, Psychiatry, Brain, GMT, Anxiety, PTSD, Neuroscience, The Company, Neurology, Pharmaceutical industry

This webinar will explore the intersection of neuroscience and psychedelics, highlighting their potential therapeutic benefits for mental health conditions such as depression, anxiety, PTSD, and addiction.

Key Points: 
  • This webinar will explore the intersection of neuroscience and psychedelics, highlighting their potential therapeutic benefits for mental health conditions such as depression, anxiety, PTSD, and addiction.
  • Dr. Reichelt will delve into the neurobiology of psychedelics, emphasizing their role in promoting neuroplasticity, which allows for the rewiring of the brain.
  • Ongoing clinical research will also be discussed, including the use of these substances in controlled settings to address trauma, reduce symptoms, and tackle substance dependence.
  • Finally, Dr. Reichelt will explore next-generation psychedelics without hallucinatory effects and the potential of psychedelics as innovative therapeutic tools in psychiatry and neurology.

Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds

Retrieved on: 
Tuesday, December 5, 2023
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Depression, Research, IND, Hallucination, Clinical trial, Serum, Mouse, Addiction, Artificial intelligence, Neuroplasticity, Investigational New Drug, Therapy, Anxiety, Permeability, HTR, Traffic barrier, Pharmaceutical industry

Enveric plans to select one of the compounds for preclinical development early in 2024 in anticipation of Investigational New Drug (IND) application for a first-in-human clinical trial.

Key Points: 
  • Enveric plans to select one of the compounds for preclinical development early in 2024 in anticipation of Investigational New Drug (IND) application for a first-in-human clinical trial.
  • Enveric’s research team successfully narrowed the EVM301 Series to three candidates with preclinical data indicating 5HT2A receptor binding, induction of neuroplasticity, and positive stress recovery outcomes in animal models showing no indication of hallucinations.
  • All three candidates demonstrated acceptable assessments of cellular toxicity, blood-brain barrier permeability, and differential binding to other serotonin receptors and transporters.
  • We are committed to aggressively pursuing a thorough and expedited preclinical program in 2024 in preparation for an IND application.”

Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 UPLIFT Study of TNX-601 ER for the Treatment of Major Depressive Disorder

Retrieved on: 
Monday, October 16, 2023
Weight gain, Food, Active ingredient, Brain, Neuron, GM, Atrophy, Society, Peroxisome, DSM-IV codes, Medicine, FDA, ITT, Neuroplasticity, Depression, Tonix Pharmaceuticals, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MDD, PPAR, Oxidative stress, Pharmaceutical industry, Tianeptine

CHATHAM, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced the completion of the clinical phase of the Phase 2 potential registration-quality, double-blind, randomized, multicenter, placebo-controlled UPLIFT1 study of TNX-601 ER2 (tianeptine hemioxalate extended-release tablets) as a potential treatment for major depressive disorder (MDD). Topline results from the intention-to-treat (ITT) sample (N=132) are expected in early November 2023.

Key Points: 
  • Topline results from the intention-to-treat (ITT) sample (N=132) are expected in early November 2023.
  • TNX-601 ER is being developed as a monotherapy and first-line treatment for MDD and works by a distinct mechanism of action as compared to traditional monoaminergic antidepressants.
  • Tonix recently reported that tianeptine activates peroxisome proliferator-activated receptors PPAR-β/δ and PPAR-γ.
  • “Tianeptine restores connectivity between neurons, or neuroplasticity, and limits the effects of oxidative stress in the brain in animal models of depression.

Enveric Biosciences to Present Poster Highlighting EVM301 Series at the International Conference on Molecular Biology and Biochemistry 2023

Retrieved on: 
Monday, September 18, 2023
Mental Health, Health, Neurology, Research, Science, Pharmaceutical, Biotechnology, Hallucination, DMT, Central nervous system, Therapy, Neuroplasticity, Enver Creek Secondary School, Catalog, Doctor of Philosophy, CNS, Addiction, Molecular biology, Biochemistry, Mexican International Conference on Artificial Intelligence, Central nervous system disease, NCE, Algorithm, Poster, Serotonin, Conference, Treatment, Pharmaceutical industry, Anxiety, Depression

The poster will be presented at the International Conference on Molecular Biology and Biochemistry 2023 (ICMBB 2023) taking place in Toronto, Canada from September 18-19.

Key Points: 
  • The poster will be presented at the International Conference on Molecular Biology and Biochemistry 2023 (ICMBB 2023) taking place in Toronto, Canada from September 18-19.
  • Enveric’s EVM301 Series encompasses new chemical entity (NCE) tryptamine pharmaceutical drug candidates designed to engage the serotonin 5HT2A receptor and other neurotransmitter receptors with the intent to promote neuroplasticity and therapeutic benefit without inducing hallucinatory effects.
  • “We are thrilled to present this compelling and promising research at ICMBB 2023, which elucidates the proprietary techniques and technologies that Enveric is employing in the advancement of our EVM301 Series,” said Dr. Joseph Tucker, President & CEO of Enveric Biosciences.
  • Our EVM301 Series of molecules includes features based on our key insights into the mechanisms of neuroplasticity,” said Dr. Hagel.

Enveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives

Retrieved on: 
Monday, September 11, 2023
Other Health, Research, General Health, Pharmaceutical, Mental Health, Technology, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Other Science, Health, NCE, Depression, Hallucination, Therapy, Neuroplasticity, Anxiety, 3D, Hallucinogen, Addiction, Patent, Patient, Artificial intelligence, Pharmaceutical industry

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced the filing of a provisional patent application to support its use of artificial intelligence (AI) based computational methods for identifying tryptamine derived new chemical entities (NCEs) and modeling interaction with the 5-HT2A receptor (5-HT2AR).

Key Points: 
  • Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced the filing of a provisional patent application to support its use of artificial intelligence (AI) based computational methods for identifying tryptamine derived new chemical entities (NCEs) and modeling interaction with the 5-HT2A receptor (5-HT2AR).
  • Enveric is currently applying these new computational methods to predict which NCEs from its EVM301 Series offer the potential to minimize or eliminate 5-HT2AR-elicited hallucination, while providing potentially efficacious treatments for critical mental health conditions.
  • “These novel computational methods offer the potential to identify drug candidates that are optimized to induce neuroplastic changes to address critical mental health disorders while minimizing unwanted side effects and safety concerns.
  • Hallucinations associated with most psychedelic and psychedelic-inspired molecules limit patients access to treatment, given the complicated, costly and time-intensive requirements to monitor patients undergoing therapy.

Professional Athletes Partner With Mind and Brain Fitness Company NESTRE

Retrieved on: 
Wednesday, September 13, 2023
Science, Athlete, Health, Neuroplasticity, Mental, Wellness, Pharmaceutical industry

LAKE NONA, Fla., Sept. 13, 2023 /PRNewswire-PRWeb/ -- NESTRE, a leading health and performance lifestyle and wellness company, and its founder, Dr. Tommy Shavers introduced four new ambassadors: Robert Griffin III, Gabriel Davis, Chole Abbott, and Malcolm Jenkins this week. The newest ambassadors, each highly accomplished in their fields, embody the essence of NESTRE's commitment to a healthy and vibrant lifestyle, dedicated to wellness from the neck up.

Key Points: 
  • Celebrated athletes including Robert Griffin III, Gabriel Davis, Chole Abbott, and Malcolm Jenkins Team Up with NESTRE to Promote Mental and Cognitive Training as the Next Frontier in Human Health, Wellness, and Performance.
  • LAKE NONA, Fla., Sept. 13, 2023 /PRNewswire-PRWeb/ -- NESTRE , a leading health and performance lifestyle and wellness company, and its founder, Dr. Tommy Shavers introduced four new ambassadors: Robert Griffin III, Gabriel Davis, Chole Abbott, and Malcolm Jenkins this week.
  • Together, we will empower others to make positive changes in their lives, by making mind and brain fitness a lifestyle."
  • "With NESTRE, I believe we can truly change the game and get on the leading edge of personalized mental and cognitive performance solutions."

Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study

Retrieved on: 
Tuesday, August 8, 2023
Molecule, Neuron, Rat, DMT, CSE, DMT: The Spirit Molecule, Depression, Neuroplasticity, Stroke, Clinical trial, Penile spines, AGN, Pharmacokinetics, Brain, Biomarker, Signal transduction, Plasma, Ethics, Patient, Growth, Diagnosis, BDNF, Death, Imperial College London, CHDR, Safety, Pharmaceutical industry

VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro), has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2 DMT Stroke study.

Key Points: 
  • VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro), has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2 DMT Stroke study.
  • The Phase 2 human stroke trial will study an intravenous sub-psychedelic dose of DMT in patients who are hospitalized after having suffered an acute ischemic stroke.
  • Algernon consultant Dr. Rick Strassman, DMT research pioneer and author of the books DMT: The Spirit Molecule and The Psychedelic Handbook commented: “I am encouraged by the results of Algernon’s Phase 1 study in which a prolonged infusion of DMT achieved the desired pharmacokinetics.
  • “We are investigating DMT as a potential new therapeutic treatment that could have a positive impact on ischemic stroke patients worldwide.”

NeuroSolv Therapeutics Developing New Therapy to Treat Spinal Cord Injury, Partners With AscellaHealth to Bring Therapy to Market

Retrieved on: 
Tuesday, July 11, 2023
Research, Surgery, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Injection, Neuron, Partnership, American Spinal Injury Association, Neuroplasticity, Tetraplegia, Spinal cord, Multimedia, Pharmacy, Ventilation, EMA, Patient, Synapse, European Medicines Agency, Therapy, World Health Organization, Pharmaceutical industry, Medical device, Dentistry, Health insurance

By temporarily removing the protective perineuronal net on the surface of spinal cord neurons, new synapses can be created.

Key Points: 
  • By temporarily removing the protective perineuronal net on the surface of spinal cord neurons, new synapses can be created.
  • In addition, the treatment removes signal-blocking glial scars on the surface of spinal cord neurons to enable new synapses to be made.
  • Within the UK alone, there are 50,000 people living with a life-changing spinal cord injury according to the Spinal Injury Association.
  • The team is also looking to partner with spinal cord injury associations and sports injury organisations to bring awareness to advancements in treatments.

HARMONIC BIONICS ANNOUNCES COMMERCIAL LAUNCH OF THE HARMONY SHR™ ROBOTIC REHABILITATION SYSTEM FOLLOWING FDA REGISTRATION

Retrieved on: 
Tuesday, April 18, 2023
Wearable, Stroke, Bionics, Mechanical engineering, AOTA, Rehabilitation, American Occupational Therapy Association, Ascending limb of loop of Henle, Assistant, Harmony, Auburn University, Occupational therapy, Patient, DSM-IV codes, Neuroplasticity, SHR, Robotics, FDA, Conference, Medical device, Nursing

AUSTIN, Texas, April 18, 2023 /PRNewswire/ -- Rehabilitation robotics company Harmonic Bionics announced today that the company has registered their flagship exoskeleton Harmony SHR™ with the FDA as a Class II 510(k)-exempt device.

Key Points: 
  • AUSTIN, Texas, April 18, 2023 /PRNewswire/ -- Rehabilitation robotics company Harmonic Bionics announced today that the company has registered their flagship exoskeleton Harmony SHR™ with the FDA as a Class II 510(k)-exempt device.
  • The Harmony SHR Robotic Rehabilitation System works with a patient's scapulohumeral rhythm (SHR) to enable natural, comprehensive therapy for both arms.
  • Harmonic Bionics will be demonstrating the Harmony SHR system later this week in booth 126 at AOTA Inspire, the largest occupational therapy conference in the country.
  • For more information on Harmonic Bionics and Harmony SHR, please visit www.harmonicbionics.com .